#USA #New York #Gross Law Firm #REGENXBIO #RGNX

Gross Law Firm's Class Action Notification

The Gross Law Firm has recently issued a notification aimed at the shareholders of REGENXBIO Inc. (NASDAQ: RGNX), urging them to take action regarding a potential class action lawsuit. This legal action comes in response to significant allegations against the company, with the timeline for investors to register rapidly approaching.

Background of the Allegations

The claims in this lawsuit pertain to the company's promises regarding its gene therapy product candidate, RGX-111, which is intended for the treatment of severe Mucopolysaccharidosis Type I, commonly referred to as Hurler syndrome. Investors were reportedly reassured about the expected success of RGX-111, backed by favorable preliminary results from ongoing clinical studies. Moreover, REGENXBIO made numerous optimistic statements regarding the therapy's efficacy while allegedly concealing vital information about its safety and potential risks.

On January 28, 2026, these issues escalated when REGENXBIO disclosed that the FDA had imposed a clinical hold on the RGX-111 therapeutic investigation. The announcement indicated that a CNS tumor had been discovered in a patient enrolled in the trial, which led to significant turmoil in the stock market. Following this announcement, shares of REGENXBIO dropped precipitously from $13.41 to $11.01 in a single day, reflecting a staggering decline of 17.8%.

Call for Action for Shareholders

The Gross Law Firm is advocating for shareholders who acquired shares of REGENXBIO between February 9, 2022, and January 27, 2026, to engage with them directly for possible lead plaintiff designation. It’s crucial to note that being appointed as a lead plaintiff is not mandatory to benefit from any financial recovery that may arise from the lawsuit.

The deadline for shareholders looking to participate in this class action is fast approaching, with April 14, 2026, marking the final date to express interest in the lead plaintiff role. To assist shareholders in tracking developments in the case, the law firm promises to enroll them in a portfolio tracking system, providing detailed updates as the case progresses.

Why Choose Gross Law Firm?

The Gross Law Firm is renowned for its commitment to protecting investors' rights, especially for those who have faced losses due to fraudulent activities and deceptive practices by corporations. The firm's mission emphasizes accountability and responsible conduct by corporations, aiming to secure recovery for investors impacted by misleading claims.

Investors who have suffered losses in REGENXBIO due to the company's alleged misconduct are encouraged to assess their options promptly. Engaging with a law firm that possesses experience in class action lawsuits can be pivotal in navigating a complex legal landscape and ensuring that all avenues for recovery are explored.

How to Register

To register for participation or gain more information, shareholders can visit the Gross Law Firm's website or contact them directly for assistance. Given the looming deadline, they are advised not to procrastinate in taking these critical steps to safeguard their investments.

Contact Information:
Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

In conclusion, investors should act swiftly to ensure their rights are protected as the lawsuit unfolds. The time-sensitive nature of this notification stresses the importance of staying informed and poised to act.